MAR Oncology and Hematology (2026) 6:2
Review Article

Novel Insights in Colorectal Cancer Treatment: 2026 Advances and Persisting Challenges

Abdelaziz AMMARI *[1], Zineb BAAZIZ [1], Sihem BENSALEM [2], Walid TIBERMACINE [3], Assia BENSALEM [1]

1. *Department of Medical Oncology, Public Hospital Didouche Mourad, University of Constantine 3, ALGERIA.*
2. *Endocrinology-Diabetology and Metabolic diseases, Regional University Military Hospital, Commander Abdellali BENBAATOUCHE (HMRUC) Constantine, ALGERIA.*
3. *Department of Radiology, University Hospital of Constantine, University of Constantine 3, ALGERIA.*

*__Correspondence to__: Abdelaziz AMMARI, Department of Medical Oncology, Public Hospital Didouche Mourad, University of Constantine 3, ALGERIA.

Received: 10 February 2026

Published: 01 March 2026

DOI: https://doi.org/10.5281/zenodo.18829854

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality worldwide, with outcomes increasingly shaped by molecular stratification, evolving perioperative paradigms, and expanding systemic treatment options. By 2026, "novel insights" in CRC treatment are less defined by any single breakthrough than by the convergence of refined genomic/immune subtyping that operationalizes precision sequencing, broadened targeted and antibody-based therapeutic platforms (including antibody–drug conjugates and next-generation antibodies), and translational deployment of circulating tumor DNA (ctDNA), organoid models, and artificial intelligence (AI) to inform diagnosis, prognosis, and treatment selection. Persisting challenges—tumor heterogeneity, immune resistance in pMMR/MSS disease, therapy-associated toxicity, and lack of standardization across emerging technologies—continue to constrain durable benefit for many patients. This narrative review synthesizes 2026-era advances in CRC management and highlights key obstacles and research priorities.

Keywords

Colorectal cancer; metastatic colorectal cancer; precision oncology; ctDNA; minimal residual disease; immunotherapy; HER2; RAS; BRAF; antibody–drug conjugate; tumor microenvironment; organoids; artificial intelligence.

Introduction

CRC arises through a multistep process of genomic and epigenomic alterations interacting with host immune surveillance and environmental exposures. Canonical carcinogenic pathways include chromosomal instability (CIN), mismatch repair deficiency with microsatellite instability (dMMR/MSI-H), and CpG island methylator phenotype (CIMP). Clinically, CRC encompasses anatomically and biologically distinct entities—right- vs left-sided colon cancers and rectal cancers—with divergent molecular frequencies, metastatic tropism, and response patterns.

In 2026, CRC care is best conceptualized as a set of biologically segmented diseases managed across a continuum that spans prevention/screening, localized therapy (endoscopic/surgical and radiotherapeutic), perioperative systemic strategies, and metastatic-line sequencing. Recent syntheses emphasize that progress is simultaneously accelerated by multi-omic discovery and slowed by practical barriers (assay standardization, real-world implementation, and resistance biology).(1)(2)

Etiology and Pathophysiology Relevant to Treatment

CRC risk reflects interplay between inherited predisposition (e.g., Lynch syndrome and other germline variants), inflammatory conditions (IBD), lifestyle factors, and age-related accumulation of somatic alterations. Tumorigenesis proceeds via adenoma–carcinoma sequences (often CIN/APC-driven) or serrated pathways (often BRAF/CIMP-associated), with additional selective pressures exerted by the immune microenvironment and therapy.

Treatment relevance follows from:

- Oncogenic drivers and pathway dependencies (e.g., RAS/RAF/EGFR axis, HER2 signaling).
- DNA repair status (dMMR/MSI-H as a strong predictor of response to immune checkpoint blockade).
- Tumor microenvironment (TME) characteristics (immune infiltration, stromal composition, angiogenic signaling) that modulate sensitivity/resistance to immunotherapy and anti-angiogenic strategies.
- Intratumoral and intermetastatic heterogeneity, a dominant mechanism underlying primary resistance, acquired resistance, and discordant responses across lesions.(1)

Clinical Presentation and Diagnostic Work-up (Treatment-Determining Elements)

CRC presentation varies by location and stage: occult bleeding/iron deficiency anemia, altered bowel habits, obstruction, weight loss, and, in rectal cancer, tenesmus/hematochezia. Metastatic disease commonly involves liver and lung; peritoneal involvement carries distinct prognostic and therapeutic implications.

Key diagnostic procedures guiding treatment include:

- Histologic confirmation with pathology review (including grade, lymphovascular/perineural invasion).
- Staging by CT chest/abdomen/pelvis; rectal MRI (and often endorectal ultrasound) for local staging; PET selectively.
- Molecular profiling increasingly performed early in metastatic disease: at minimum, dMMR/MSI status and RAS/RAF testing; additional biomarkers (HER2, NTRK and other fusions, tumor mutational burden in select contexts) per institutional pathways.
- ctDNA-based assays emerging for prognostication and minimal residual disease (MRD) assessment,

though practice integration remains variable due to assay differences and evolving evidence thresholds.(2)(3)

2026 Advances in Local and Perioperative Management

1. Colon cancer: optimizing perioperative systemic therapy

For resectable colon cancer, surgery remains the cornerstone. The "advance" is not a replacement of surgery but improved risk stratification and tailoring of adjuvant strategies through refined clinicopathologic staging, improved supportive care enabling dose intensity, and growing interest in ctDNA-informed approaches (discussed below). Contemporary reviews continue to emphasize multimodality management with ongoing evolution in adjuvant selection and duration debates in select populations.(4)

2. Rectal cancer: total neoadjuvant therapy (TNT) and organ preservation

Rectal cancer management has continued to shift toward intensified neoadjuvant approaches (TNT) for locally advanced disease, with a parallel move toward nonoperative management ("watch-and-wait") in carefully selected patients achieving clinical complete response. These approaches aim to increase complete response rates, improve systemic control, and potentially reduce the morbidity of radical surgery. Persisting issues include optimal patient selection, response assessment accuracy, surveillance intensity, and generalizability across practice settings—challenges frequently highlighted in broad CRC management reviews.(4)

2026 Advances in Systemic Therapy for Metastatic CRC

1. Cytotoxic chemotherapy: still foundational, increasingly contextual

Fluoropyrimidine-based regimens combined with oxaliplatin and/or irinotecan remain the systemic backbone. The 2026 "novelty" lies more in sequencing optimization, integration with biologics, and toxicity-mitigating strategies than in new cytotoxics. Ongoing challenges include cumulative neuropathy (oxaliplatin), diarrhea and cholinergic syndromes (irinotecan), cytopenias, and the need to preserve performance status across multiple lines.

2. EGFR and angiogenesis targeting: refining sequencing rather than reinventing

Targeting EGFR (in RAS wild-type, typically left-sided tumors) and VEGF/angiogenesis (across broader groups) remains central to first- and later-line strategy design. Persisting controversies include optimal biologic selection by sidedness and molecular profile, and how best to sequence EGFR- and VEGF-directed therapies to maximize depth of response while preserving later-line options.

3. HER2 as an actionable subgroup and a platform for antibody innovation

HER2 amplification/overexpression has matured into a clinically actionable subgroup, particularly within RAS wild-type disease. Advances include increased recognition and more robust therapeutic development across HER2-directed combinations and antibody-based modalities. Reviews focused on targeted therapy in CRC highlight the growing therapeutic relevance of HER-family inhibition and the importance of reliable HER2 testing and patient selection.(5)

4. Antibody-based therapeutics: ADCs and next-generation antibodies

A major 2026 trend is the expansion of antibody engineering—antibody–drug conjugates (ADCs), bispecifics, and nonconjugated antibodies with enhanced effector functions—aiming to overcome limited efficacy and improve therapeutic index. For CRC, these platforms offer two strategic promises: more selective tumor killing (reducing systemic exposure) and potential immune engagement or microenvironment modulation. A 2025 review summarizes CRC's transformation by antibody-based therapeutics and the rapid development of ADCs and related approaches, while also underscoring that clinical translation depends on antigen selection, resistance mechanisms, and toxicity management (e.g., off-tumor expression, payload-related adverse events).(6)

5. Immunotherapy: durable benefit in MSI-H/dMMR; persistent resistance in pMMR/MSS

The most clinically decisive immunotherapy insight remains the strong responsiveness of MSI-H/dMMR CRC to immune checkpoint inhibition. In contrast, pMMR/MSS CRC continues to exhibit limited response to checkpoint blockade alone. By 2026, this "hard problem" is increasingly framed as a microenvironment and immunobiology problem: inadequate T-cell infiltration, immunosuppressive myeloid populations, stromal barriers, and pathway-driven immune evasion. Contemporary syntheses emphasize that tumor heterogeneity and the TME are key reasons why many immunotherapy combinations produce inconsistent benefit and sometimes unacceptable toxicity outside trials.(1)(7)

Emerging Technologies Reshaping Treatment Strategy

1. ctDNA and MRD: from prognostic biomarker to decision catalyst (with caveats)

ctDNA-based MRD assessment is increasingly used to estimate recurrence risk after curative-intent therapy and to refine post-treatment surveillance and adjuvant decision frameworks. The clinical momentum is driven by the logic that molecular relapse may precede radiographic relapse and enable earlier intervention or tailored escalation/de-escalation.

However, persisting challenges limit uniform adoption:

Assay heterogeneity (tumor-informed vs tumor-naïve platforms; thresholds; sensitivity in low-shedding tumors).

Uncertainty about the optimal actionability of ctDNA positivity in specific stages and settings.

Risk of overtreatment if ctDNA-guided escalation lacks demonstrated survival benefit in a given context.

These limitations are repeatedly noted as broader "standardization and evidence-generation" bottlenecks across CRC innovation pipelines.(1)(2)

2. Organoids and functional precision oncology

Patient-derived organoids provide a functional complement to genomic profiling by offering experimentally testable models of drug sensitivity and resistance. In 2026, organoids are increasingly positioned as tools to interrogate heterogeneity, evaluate rational combinations, and study mechanisms of acquired resistance. Yet routine clinical implementation is constrained by turnaround time, cost, sample adequacy, and the absence of standardized culture conditions and clinical validation pathways—issues explicitly highlighted in recent CRC "advances and challenges" reviews.(1)

3. AI across the CRC pathway: screening, pathology, imaging, and decision support

AI applications have expanded from computer-aided polyp detection in colonoscopy to digital pathology-based feature extraction and radiology-driven prediction models (e.g., lymph node involvement, response probability, metastasis detection). In oncology decision support, the key promise is harmonization of multi-modal data (histology, genomics, imaging, ctDNA) into clinically actionable predictions. Persisting barriers include model generalizability, bias, data privacy, prospective validation, and integration into workflow without increasing clinician burden.(1)(8)

Persisting Challenges (Why Progress Is Uneven)

1. Tumor heterogeneity and clonal evolution

CRC commonly exhibits branched evolution with subclonal drivers that can mediate resistance to targeted therapies and contribute to mixed responses across metastases. Heterogeneity complicates biomarker interpretation (single-site biopsies), undermines durability of targeted approaches, and creates a moving target for immune-based therapies. This is a central, repeatedly emphasized obstacle in contemporary CRC literature, often linked to the need for longitudinal monitoring (ctDNA) and improved functional models (organoids).(1)

2. Immunotherapy resistance in pMMR/MSS disease

The limited activity of checkpoint inhibitors in pMMR/MSS CRC remains the most visible unmet need. Combination approaches are biologically plausible but often face:

1. Modest response rates not robust across studies,
2. Increased toxicity and complex management,
3. Lack of validated predictive biomarkers beyond MSI/dMMR,
4. Difficulty selecting appropriate endpoints and patient populations.

This challenge is commonly framed as a TME and immune-priming problem rather than a simple "add another drug" problem.(1)(7)

3. Toxicity, tolerability, and real-world feasibility

As regimens proliferate, cumulative toxicity becomes a primary determinant of achievable benefit—especially in older patients and those with comorbidities. The practical ability to deliver multiple lines of therapy (and to maintain performance status) can dominate outcomes as much as molecular eligibility.

4. Standardization gaps for ctDNA, organoids, and AI

Three parallel implementation challenges persist:

1. Analytic validity (assay performance and reproducibility),
2. Clinical validity (predictive/prognostic robustness),
3. Clinical utility (improved outcomes compared with standard care).

CRC is a leading "test case" for these issues, and reviews continue to highlight the lack of consensus standards as a major brake on translation.(1)(2)

5. Equity and access

Precision CRC care requires timely endoscopy, high-quality imaging, expert pathology, broad molecular testing, multidisciplinary tumor boards, and trial access. Disparities in these resources can widen outcome gaps even as therapeutic options expand.

Complications and Prognosis: What Has Changed by 2026?

CRC complications include obstruction, bleeding, perforation, thromboembolism, cancer cachexia, and treatment-related adverse events (neuropathy, cytopenias, diarrhea, hypertension/proteinuria with anti-angiogenic therapy, dermatologic toxicities with EGFR inhibition, and immune-related adverse events with checkpoint inhibitors). Prognosis is strongly stage-dependent and increasingly biomarker-dependent in the metastatic setting.

What has improved:

- More biomarker-aligned therapy (including expanding targetable subsets).
- More structured multimodality strategies (notably in rectal cancer).
- Better supportive care enabling prolonged therapy sequencing.

What remains constrained:

- Limited durable disease control for many patients with pMMR/MSS mCRC.
- Resistance and heterogeneity limiting long-term effectiveness of targeted and immune strategies.
- Implementation barriers limiting equitable application of innovations.
- These themes are consistent across recent CRC management and "advances/challenges" syntheses.(1)(4)

Future Directions (Near-Term Research Priorities)

Key priorities implied by 2026 trajectories include:

Mechanism-driven immunotherapy combinations for pMMR/MSS CRC with validated predictive biomarkers.

Longitudinal monitoring frameworks integrating ctDNA with imaging and clinical parameters to anticipate resistance and guide sequencing.

Antibody platform optimization (ADC target selection, payload engineering, and resistance mitigation).

Standardization and prospective validation for ctDNA, organoids, and AI tools, with pragmatic trial designs embedded in routine care.

Implementation science to ensure that precision CRC advances translate across diverse clinical settings.

Conclusion

In 2026, CRC treatment advances reflect an increasingly integrated precision oncology ecosystem: molecular stratification, expanding targeted and antibody-based platforms, and emerging decision tools (ctDNA, organoids, AI). Yet the field's most consequential unmet needs—immunotherapy-resistant pMMR/MSS disease, heterogeneous and evolving tumor biology, and standardization/implementation barriers—continue to limit durable population-level benefit. Progress in the next phase is likely to depend less on isolated drugs and more on validated biomarker frameworks, resistance-aware sequencing, and scalable clinical integration.

Cited Sources

1. Recent advances and challenges in colorectal cancer: From molecular research to treatment. Qi GX et al. Baishideng Publishing Group Inc. 2025
2. Recent advances and challenges in colorectal cancer: From molecular research to treatment. Qi G et al. World Journal of Gastroenterology. 2025
3. Navigating the Colorectal Cancer Maze: Unveiling Pathways To Diagnosis, Management, Pathophysiology and Prevention. Al Kamzari K, Constantinou C. Springer. 2025
4. Colorectal cancer: Recent advances in management and treatment. Fadlallah H et al. World J Clin Oncol. 2024
5. Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions. Khelwatty S. Cancers (Basel). 2025
6. Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment. G Noorkhajavi. Springer Nature Link
7. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. Kumar A et al. World J Gastrointest Surg. 2023
8. Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine. P Ahluwalia. National Institutes of Health (NIH) | (.gov)

Medtronic